Topics

Glycyx PharmaVentures, Ltd. Company Profile

10:47 EST 21st January 2020 | BioPortfolio


News Articles [103 Associated News Articles listed on BioPortfolio]

Pfizer and Wyeth’s $68bn Deal

Is the Pfizer and Wyeth deal a good move? Does this provide opportunities for other big pharma in 2009? Tibor Papp and Kevin Bottomley of PharmaVentures answer these questions and more in this specia...

PharmaTelevision: The Story So Far

In an interview with Ann Salter, Fintan Walton, CEO, PharmaVentures, looks back at the successful creation of PharmaVentures Business Review and discusses its growth and development since its launch i...

Fintan Walton & Adrian Dawkes, PharmaVentures; Will 2014 be the breakthrough year?

In this programme Adrian Dawkes talks to Fintan Walton, CEO PharmaVentures, about the recent JP Morgan Healthcare conference and the year ahead for the pharmaceutical and biotec industry. They discus...

PharmaDeals Research: Outsourcing of Deal Making Analysis

In this special feature interview, Fintan Walton talks with John Wyatt, Head of Commercial Development at PharmaVentures, about PharmaVentures' new service - PharmaDeals Research. John explains that P...

PharmaVentures CEO, Fintan Walton discusses the impact on deal-making in Q3 2010.

In this interview, PharmaVentures CEO, Fintan Walton discusses the impact on deal-making in Q3 2010 with reporter Helen Wright at the PTV studios, in Oxford, U.K.

PharmaVentures Nikki Watkins discusses Oncology with Helen Wright.

In this interview, PharmaVentures Nikki Watkins discusses Oncology with reporter Helen Wright at the PTV studios, in Oxford, U.K.

PharmaVentures Nigel Borshell discusses co-promotions with Helen Wright.

In this interview, PharmaVentures Nigel Borshell discusses co-promotions with reporter Helen Wright at the PTV studios, in Oxford, UK.

Part 3: The future of biotechs M&As: The investors' perspective

Dr Fintan Walton, CEO of PharmaVentures, asked a panel of leading industry fund managers how they are tailoring funds to ensure maximum return and the future of biotech M&A. They discuss: · ...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [5 Associated Companies listed on BioPortfolio]

Glycyx PharmaVentures, Ltd.

PharmaVentures Ltd

PharmaVentures is a premier transaction advisory firm; a world leader in partnering, M&A deals and strategic alliances. Our unrivalled bank of specialist experience, deal analytic...

PharmaVentures Limited

PharmaVentures is a leading results-driven strategic corporate and business development consultancy assisting pharmaceutical and biotechnology companies worldwide, focusing on all aspects of deal-maki...

PharmaVentures Limited & Matrix Corporate Capital

PharmaVentures Limited (http://www.pharmaventures.con) is based in Oxford, England and is a leading international corporate advisory firm supporting its clients' growth ambitions through licensing...

PharmaVentures Inc.

PharmaVentures is a leading results-driven strategic corporate and business development consultancy assisting pharmaceutical and biotechnology companies worldwide. PharmaVentures focuses on all aspect...

More Information about "Glycyx PharmaVentures, Ltd." on BioPortfolio

We have published hundreds of Glycyx PharmaVentures, Ltd. news stories on BioPortfolio along with dozens of Glycyx PharmaVentures, Ltd. Clinical Trials and PubMed Articles about Glycyx PharmaVentures, Ltd. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Glycyx PharmaVentures, Ltd. Companies in our database. You can also find out about relevant Glycyx PharmaVentures, Ltd. Drugs and Medications on this site too.

Quick Search

Corporate Database Quicklinks



Searches Linking to this Company Record